VCEL Earnings Date: Nov 5, 2026 (Estimated) — Vericel Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is VCEL's next earnings date?
Vericel Corporation (VCEL) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.06 on revenue of $77.9M.
How did VCEL do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Vericel Corporation posted EPS of $0.04 versus the -$0.03 estimate, a beat of 233.3%. Revenue was $77.5M against a $72.5M estimate. The stock's 1-day post-earnings move was +2.1%.
How much does VCEL stock move after earnings?
VCEL beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.3% (up or down) in the day after earnings.
About Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.03 | 0.04 | +233.33% | $77.5M | ✅ Beat | +2.12% | -2.70% | -11.67% |
| 2026-05-07 | Q1 2026 | -0.15 | -0.12 | +20.00% | $68.4M | ✅ Beat | -4.49% | -10.71% | -1.31% |
| 2026-02-26 | Q4 2025 | 0.41 | 0.45 | +9.76% | $92.9M | ✅ Beat | +1.59% | -5.74% | -16.90% |
| 2025-11-06 | Q3 2025 | -0.02 | 0.10 | +600.00% | $67.5M | ✅ Beat | +4.17% | +8.71% | -2.61% |
| 2025-07-31 | Q2 2025 | -0.04 | -0.01 | +75.00% | $63.2M | ✅ Beat | -14.07% | -10.75% | -11.73% |
| 2025-02-27 | Q4 2024 | 0.34 | 0.38 | +11.76% | $75.4M | ✅ Beat | -6.11% | -2.50% | -12.83% |
| 2024-11-07 | Q3 2024 | -0.05 | -0.02 | +60.00% | $57.9M | ✅ Beat | +4.14% | +15.47% | +17.34% |
| 2024-08-01 | Q2 2024 | -0.08 | -0.10 | -25.00% | $52.7M | ❌ Miss | -5.94% | -10.31% | +2.04% |
Showing last 8 quarters.